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Abstract
Based on database searches of DNA sequences, we previously reported a gene encoding peptides possessing Arg-Phe-NH2 (RFamide) at
their C termini. This gene, RFamide-related peptide (RFRP), was expected to encode several different peptides (i.e., RFRP-1, -2, and -3). In the
present study, we purified endogenous RFRP-3 from bovine hypothalamus, and demonstrated that it consisted of 28 amino acid residues. After
constructing a sandwich enzyme immunoassay for RFRP-3, we analyzed the tissue distribution of endogenous RFRP-3 in rats and found its
concentration to be highest in the hypothalamus. In binding assays, [125I]-labeled RFRP-3 bound to OT7T022 with high affinity, but its binding
affinity to HLWAR77 was low. On the other hand, [125I]-labeled neuropeptide FF (NPFF) bound to both OT7T022 and HLWAR77 with high
affinity. By serial deletion in the N-terminal portions of RFRP-3 and NPFF, we found that four C-terminal amino acid residues (i.e.,
PQRFamide), which were common between the two peptides, comprised a core sequence responsible for binding with the receptors, whereas
three amino acid residues (i.e., PNL in RFRP-3 and LFQ in NPFF) added to the N terminus of PQRFamide played crucial roles in the agonistic
activities of RFRP-3 and NPFF for OT7T022 and HLWAR77, respectively.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Biologically active peptides having RFamide structures at
their C termini are found widely in the animal kingdom from
invertebrates to mammals, and are generally referred to as
‘RFamide peptides’. We have previously reported the iden-
tification of a novel mammalian RFamide peptide gene which
we named RFamide-related peptide (RFRP) [1]. Employing
bioinformatics, we isolated it originally from databases of
human genomic and cDNA sequences. RFRP preproproteins
encoded by the human or bovine gene have been expected to
generate three kinds of mature peptides through processing,
that is, RFRP-1, -2, and -3. However, in the case of rats, only
RFRP-1 and RFRP-3 are expected to be generated. Synthetic
RFRP-1 and RFRP-3 have been demonstrated to bind to the
G protein-coupled receptor (GPCR), OT7T022, and to sup-
press forskolin-induced cAMP production in Chinese ham-
ster ovary (CHO) cells expressing OT7T022. As RFRP is
mainly distributed in the rat’s central nervous system (i.e.,
hypothalamus), it is thought to play a role in the regulation of
the endocrine system [1]. In another previous paper, we
purified endogenous RFRP-1 from bovine hypothalamic
tissue extracts, and demonstrated that endogenous bovine
RFRP-1 consisted of 35 amino acid residues [2].
In the present study, we prepared an antibody for the C-
terminal portion of RFRP-3, and purified endogenous
RFRP-3 from bovine hypothalamic tissue extracts on the
basis of immunoreactivity to this antibody. We then deter-
mined the molecular structure of bovine endogenous RFRP-
3. We also analyzed the tissue distribution of endogenous
RFRP-3 in rats by enzyme immunoassay (EIA). OT7T022
and HLWAR77 receptors are highly homologous, and both
receptors have been reported to interact with neuropeptide
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FF (NPFF) [3–5]. We therefore examined the differences
between RFRP and NPFF in their interaction with these two
receptors. Finally, we analyzed the amino acid residues of
these peptides to determine those critical for receptor inter-
action.
2. Materials and methods
2.1. Peptides
Human RFRP-1 (SLNFEELKDWGPKNVIKMSTPAV-
NKMPHSFANLPLRFamide: hRFRP-1-37), human RFRP-
3 (ATANLPLRSGRNMEVSLVRRVPNLPQRFamide:
hRFRP-3-28), human RFRP-3(21–28)amide (VPNLPQR-
Famide: hRFRP-3-8), human RFRP-1(26–37)amide (MPH-
SFANLPLRFamide: hRFRP-1-12), rat Cys-RFRP-3(13–20)
amide (CFPSLPQRFamide: rRFRP-3C), rat RFRP-3(4–20)-
Cys (NMEAGTMSHFPSLPQRFC: rRFRP-3N), and rat
SPR-RFRP-3 (SPRARANMEAGTMSHFPSLPQRFamide:
rRFRP-3-23) were synthesized using an automatic peptide
synthesizer (Model 430, PE Biosystems) as described pre-
viously [1,6]. Bovine RFRP-3 (AMAHLPLRLGKN-
REDSLSRWVPNLPQRFamide: bRFRP-3-28), bovine
RFRP-1 (SLTFEEVKDWAPKIKMNKPVVNKMPPSAA-
NLPLRFamide: bRFRP-1-35), NPFF (FLFQPQRFamide),
bovine neuropeptide AF (AGEGLSSPFWSLAAPQR-
Famide: NPAF), bovine SPA-NPFF (SPAFLFQPQRFamide:
bNPSF), human SQA-NPFF (SQAFLFQPQRFamide:
hNPSF), bovine prolactin-releasing peptide (PrRP) with
20-amino acid length (TPDINPAWYAGRGIRPVGRF-
amide: bPrRP20), PQRFamide, and LPLRFamide were
purchased from commercial suppliers (Peptide Institute or
Bachem).
N-terminal truncated peptides, that is, human RFRP-
3(22–28)amide (PNLPQRFamide: hRFRP-3-7), human
RFRP-3(23–28)amide (NLPQRFamide: RFRP-3-6), human
RFRP-3(22 – 28)amide (LPQRFamide: hRFRP-3-5),
bNPSF(2–11)amide (PAFLFQPQRFamide: bNPSF-10),
bNPSF(3 –11)amide (AFLFQPQRFamide: bNPSF-9),
NPFF(2–8)amide (LFQPQRFamide: NPFF-7), NPFF(3–
8)amide (FQPQRFamide: NPFF-6), and NPFF(4–8)amide
(QPQRFamide: NPFF-5) were prepared from hRFRP-3-8 or
bNPSF by Edman degradation as described elsewhere [7].
2.2. Immunological procedures
A monoclonal antibody for the C-terminal portion of
RFRP-3 was prepared according to our previously described
method [2,8]. Briefly, rRFRP-3C was conjugated with
bovine serum albumin (BSA) and then used as an antigen
to immunize mice. By fusing myeloma and spleen cells from
the immunized mice, we obtained a hybridoma cell clone
(7F6) that produced an antibody for rRFRP-3C. A compet-
itive EIA to detect RFRP-3 was constructed by utilizing the
monoclonal antibody and horseradish peroxidase (HRP)-
conjugated rRFRP-3C as a tracer. In this competitive EIA,
we used hRFRP-3-8 as a reference to quantify RFRP-3.
To quantify rat endogenous RFRP-3, we constructed a
sandwich EIA by a procedure similar to that which we
previously used to construct EIA for rat endogenous
RFRP-1 [2]. Briefly, we prepared a rabbit polyclonal anti-
body for the N-terminal portion of rat RFRP-3 by immuniz-
ing rRFRP-3N conjugated with BSA. The Fab fragment of
the polyclonal anti-rRFRP-3N antibody was labeled with
HRP, and then used for constructing the sandwich EIA with
monoclonal 7F6 antibody. Rat tissue extracts subjected to the
sandwich EIA for RFRP-3 were prepared by the same
method used to quantify RFRP-1 [2]. The monoclonal anti-
body was coated onto 96-well microplates, following which
the tissue extracts were added to the wells and the plates were
incubated at 4 jC for 24 h. After the HRP-conjugated anti-rat
RFRP-3N Fab was added to the wells, the plates were
incubated again at 4 jC for 16 h. HRP activity trapped in
each well was then measured. To quantify rat endogenous
RFRP-3, we used rRFRP-3-23 as a reference.
2.3. Chromatography
Bovine hypothalamic tissues (2 kg) were boiled, homo-
genized in 1 M acetic acid, and extracted overnight. The
resultant supernatant was collected by centrifugation. After
adding 0.05% trifluoroacetic acid (TFA), the solution was
applied to a Preparative C18 column (Waters) and elution
was performed using stepwise increments of 10%, 30%, and
50% CH3CN with 0.1% TFA. The immunoreactive RFRP-3
(ir-RFRP-3) content was determined by the competitive EIA
described above. Ir-RFRP-3-positive fractions were eluted at
30% CH3CN. They were then further fractionated by a
HiPrep CM-Sepharose FF (Amersham Pharmacia Biotech)
column with stepwise increments of 0.1, 0.2, 0.5, and 1.0 M
NaCl in 20 mM CH3COONH4 (pH 4.7) containing 10%
CH3CN. After precipitation with acetone, the fraction eluted
at 0.2 M NaCl was serially fractionated through high-
performance liquid chromatography (HPLC) using a
RESOURCE RPC column (Amersham Pharmacia Biotech)
with a linear gradient from 10% to 30% CH3CN with 0.1%
TFA, and a TSK-gel CM-2SW column (Toso) with a linear
gradient from 0.2 to 0.6 M NaCl in 20 mM CH3COONH4 at
pH 4.7. The resultant fractions containing ir-RFRP-3 were
finally applied to HPLC using a ARPC C2/C18 SC 2.1/10
column (Amersham Pharmacia Biotech) in a SMARTsystem
(Amersham Pharmacia Biotech).
2.4. Sequencing and mass spectrometry
Sequencing of the purified peptides was performed on a
491cLC Protein Sequencer (PE Applied Biosystems). Elec-
trospray ionization mass spectrometry (ESI-MS) and ESI-
MS/MS were preformed on an LCQ ion-trap mass spectro-
meter (Thermoquest) equipped with a nanospray ion source
(Protana).
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2.5. Receptor binding assays
For receptor binding assays, CHO cells expressing either
human OT7T22 (hOT7T022) or HLWAR77, and [125I]
hRFRP-3-8 were prepared according to our method
described previously [1,6]. [125I]NPFF was purchased from
Amersham Pharmacia Biotech (IM345).
2.6. cAMP production assays
The inhibitory activities of the peptides on forskolin-
induced cAMP production in CHO cells expressing hOT7-
T022 or HLWAR77 were determined by our method
described previously [1,9].
3. Results
3.1. Purification of endogenous RFRP-3 from bovine hypo-
thalamus
To detect endogenous bovine RFRP-3, we prepared a
mouse monoclonal antibody, (7F6 with IgG1 heavy and n
light chains) that was capable of recognizing the C-terminal
portion of RFRP-3, and then used this antibody to construct a
competitive EIA. The EIA detected hRFRP-3-8, PQRF-
amide, NPFF, and NPAF, but failed to detect hRFRP-1-12,
LPLRFamide, bPrRP20, and PQRF-OH (data not shown).
These results indicate that the EIA detected the epitope,
PQRFamide, which is the consensus C-terminal sequence
shared among RFRP-3, NPFF, and NPAF. We therefore
employed this EIA to pursue bovine endogenous RFRP-3
in every purification step.
Having previously succeeded in purifying endogenous
RFRP-1 from bovine hypothalamic tissue extracts [2], we
employed the same tissue as a starting material to purify
endogenous RFRP-3. Purification was performed with a
combination of various chromatographies through monitor-
ing ir-RFRP-3 with the competitive EIA. In CM-Sepharose
FF column chromatography, ir-RFRP-3 was eluted mainly at
0.1 and 0.2 M NaCl (data not shown). As the amounts of ir-
RFRP-3 were greater in the fractions eluted at 0.2 M than at
0.1 M NaCl, we first performed purification on the former.
Fig. 1 shows the profile of the final chromatography with
HPLC using a ARPC C2/C18 SC 2.1/10 column. Ir-RFRP-3
was mainly eluted in fraction numbers 22 and 23. As fraction
number 23 appeared to contain fewer impurities than number
22, we subjected it to microsequencing and mass spectrom-
etry. As shown in Fig. 2A, microsequencing revealed the N-
terminal sequence, AMAHLPLRLGKNREDSLSRWV,
which corresponded to the sequence from Ala104 to
Val124 in the bovine RFRP preproprotein [2]. Considering
this N-terminal sequence together with the C-terminal struc-
ture deduced on the basis of immunoreactivity, the purified
RFRP-3 was expected to consist of 28 amino acid residues,
that is, AMAHLPLRLGKNREDSLSRWVPNLPQRF-
amide. Using ESI-MS, we detected the signals of the multi-
ple charged ions (i.e., M + 6H6 +, M+ 5M5 + and M+ 4H4 +)
which would be expected from this structure (Fig. 2B). From
Fig. 1. Profile of ARPC C2/C18 SC 2.1/10-column chromatography in
purification of endogenous RFRP-3. The amount of ir-RFRP-3 in each
fraction detected with the competitive EIA is shown as a solid column. The
dotted and jagged lines indicate the percentage of CH3CN and absorbance,
respectively. Arrowheads indicate the fraction numbers.
Fig. 2. Structural analyses for purified endogenous bRFRP-3. (A) Yield of
phenylthiohydantoin (PTH)-amino acid at each cycle in Edman degradation.
(B) ESI mass spectrum showing the multiply charged ions. Purified bRFRP-
3 (11 pmol) was dissolved in 3 Al of 50% CH3CN with 1% CH3COOH,
loaded in a gold-coated capillary, and analyzed with a LCQ mass
spectrometer. Based on each m/z value of the multiply charged ion signals,
the molecular weight of bRFRP-3 was calculated using Bioworks software.
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these signals, the molecular weight of the purified RFRP-3
was determined to be 3302.3F 0.4, which agreed well with
the calculated molecular weight of 3301.8. By conducting
ESI-MS/MS analysis for M+ 5M5 + (m/z 661) as a precursor
ion, we confirmed the above 28-amino acid length RFRP-3
sequence with the b- and y-ions which would be expected
(data not shown).
We subsequently purified the fractions eluted at 0.1 M
NaCl in the CM-Sepharose FF column chromatography. By
ESI-MS and microsequencing, the main immunoreactive
peak of the final chromatography was revealed to be
SPAFLFQPQRFamide, the three-amino acid prolonged form
of NPFF (data not shown). As RFRP-3 and NPFF both
possess the same C-terminal structure detected by our EIA,
we concluded that NPFF was obtained by the purification.
3.2. Analyses for the distribution of RFRP-3 in rat tissues
Comparing the sequences of bovine and rat prepropro-
teins [1,2], endogenous bovine RFRP-3 with 28-amino acid
length seemed to correspond to rat RFRP-3 with 23-amino
acid length (i.e., rRFRP-3-23). To quantify rat endogenous
RFRP-3, we prepared an antibody for its N-terminal portion
by immunizing rRFRP-3N. The antibody recognized
rRFRP-3-23 and rRFRP-3-17, but neither rRFRP-1-37,
NPFF, nor NPAF (data not shown). By utilizing both this
antibody labeled with HRP and the monoclonal antibody
7F6, we constructed a sandwich EIA to quantify rat endog-
enous RFRP-3. This sandwich EIA detected at least 5 fmol/
well of rRFRP-3-23. However, it did not detect other
peptides with the RFamide structure, including rRFRP-1-
37, NPFF, or NPAF (data not shown). These results indicate
that it specifically detected rat endogenous RFRP-3.
Using the sandwich EIA, we measured rat endogenous
RFRP-3 in various tissues. As shown in Fig. 3, significant
levels of ir-RFRP-3 were detected in the central nervous
system, with its highest concentration found in the hypo-
thalamus (1800 fmol/g wet tissue). High concentrations of ir-
RFRP-3 were detected in the thalamus (1300 fmol/g wet
tissue) and midbrain (750 fmol/g wet tissue). Moderate
levels of ir-RFRP-3 were detected in the cerebral cortex
(150 fmol/g wet tissue), striatum (240 fmol/g wet tissue),
medulla oblongata (310 fmol/g wet tissue), and pituitary
grand (150 fmol/g wet tissue), and a low level in the
cerebellum (20 fmol/g wet tissue). It was, however, unde-
tectable ( < 20 fmol/g wet tissue) in the hippocampus, eye-
ball, peripheral tissues, and plasma.
3.3. Scatchard analyses for binding of [125I]RFRP-3 and
[125I]NPFF with OT7T022 and HLWAR77
HLWAR77 has been reported as a receptor for NPFF [3]
and shows high homology with hOT7T022 (56% according
to a Gapped Blast program). We therefore examined the
interactions of both RFRP-3 and NPFF with hOT7T022 and
HLWAR77. In Scatchard analyses, [125I]hRFRP-3-8 bound
with hOT7T022 (Fig. 4A) at the Kd value of 270 pM, but
significant binding was not detected with HLWAR77 (Fig.
4B). On the other hand, [125I]NPFF significantly bound with
both hOT7T022 (Fig. 4C) and HLWAR77 (Fig. 4D) at the
Kd values of 680 and 240 pM, respectively.
3.4. Properties of RFRP-3 and NPFF in interaction with
receptors
We prepared various lengths of C-terminal peptides of
RFRP-3 and NPFF, and analyzed their interactions with
Fig. 3. Quantification of endogenous RFRP-3 in rat tissues by EIA. The ir-
RFRP-3 contents were determined with the sandwich EIA. A calibration
curve for quantification was obtained by using synthetic rat RFRP-3-23.
Data are expressed as the meanF S.E. in multiple assays (n= 4 or 5).
Fig. 4. Scatchard analyses for the binding of radiolabeled human RFRP-3
and NPFF to hOT7T022 and HLWAR77. The membrane fractions prepared
from CHO-hOT7T022 (A, C) and CHO-HLWAR77 (B, D) cells were
incubated with increasing concentrations of 125I-labeled hRFRP-3-8 (A, B)
or NPFF (C, D), and the bound and free ligands were separated when binding
reached equilibrium. Data are plotted as bound (B, pmol mg 1 protein)
versus bound/free (B/F, pmol mg 1 nM) radiolabeled ligands. Each symbol
represents the mean value with standard error in triplicate determinations.
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hOT7T022 and HLWAR77 (Table 1). To assess the inter-
action, we performed competitive binding and cAMP-pro-
duction-inhibitory assays. Competitive binding assays were
performed to determine binding affinity in combinations of
[125I]hRFRP-3-8 with hOT7T022 and [125I]NPFF with
HLWAR77, respectively. cAMP-production-inhibitory
assays with CHO cells expressing hOT7T022 or HLWAR77
were performed to determine each peptide’s agonistic activ-
ity. Bovine endogenous RFRP-3 (bRFRP-3-28), hRFRP-3-
31, and hRFRP-3-28 showed similar profiles in their inter-
action with the receptors. These peptides efficiently
inhibited the binding of [125I]hRFRP-3-8 to hOT7T022 at
median inhibitory concentrations (IC50) of 1–2 nM. They
showed potent cAMP-production-inhibitory activity on
hOT7T022 at median effective concentrations (EC50) of
around 5 nM. The IC50 values of these peptides in the
binding of [125I]hRFRP-3-8 to HLWAR77 ranged from 7 to
16 nM. On the other hand, their cAMP-production-inhib-
itory activities on HLWAR77 were from 40 to 100 times
weaker than those on hOT7T022. A similar pattern was
observed for the interaction of hRFRP-1-37 and bovine
endogenous RFRP-1 (bRFRP-1-35) with hOT7T022 and
HLWAR77, although the binding activity of RFRP-1 on
hOT7T022 appeared to be slightly weaker than that of
RFRP-3. Human and bovine peptides were almost equipo-
tent in these assays. Our results suggest that RFRPs are
principally directed to hOT7T022 rather than HLWAR77,
though they cross-react with HLWAR77 to some extent.
By serially deleting the N-terminal portion of RFRP-3, we
isolated the sequence critical for interaction with the recep-
tors. In the assays of binding affinity and cAMP-production-
inhibitory activity on hOT7T022, hRFRP-3-8 and hRFRP-3-
7 were almost equivalent to hRFRP-3-17, hRFRP-3-31, and
hRFRP-3-28, suggesting that the seven-residue C-terminal
peptide, PNLPQRFamide, was sufficient for full interaction
with hOT7T022. However, in the assays of binding affinity
and cAMP-production-inhibitory activity on HLWAR77, the
interactions of hRFRP-3-8 and hRFRP-3-7 appeared to be
attenuated by the deletion of the N-terminal sequence,
suggesting that RFRP-3 interacted with HLWAR77 in a
different manner than with hOT7T022. The potency of
hRFRP-3-6 and hRFRP-3-5 reduced to about one-tenth that
of hRFRP-3-7 in cAMP-production-inhibitory activity on
CHO cells expressing hOT7T022, suggesting that Pro at the
N terminus of hRFRP-3-7 was important for exhibiting full
cAMP-production-inhibitory activity on hOT7T022. Al-
though the four-residue C-terminal peptide of RFRP-3
(hRFRP-3-4: PQRFamide) — identical to that of NPFF
(NPFF-4) — still retained a weaker but evident binding
activity to hOT7T022 (IC50 = 15 nM), its cAMP-production-
inhibitory activity on hOT7T022 was almost completely
eliminated, suggesting that Leu at the N terminus of
RFRP-3-5 is crucial for cAMP-production-inhibitory activ-
ity on hOT7T022. It is notable that the five-amino acid
residue C-terminal peptide of RFRP-1 (hRFRP-1-5:
LPLRFamide) showed a profile similar to hRFRP-3-5 in
Table 1
Comparison between RFRP-3 and NPFF in their interactions with hOT7T022 and HLWAR77 by competitive binding and cAMP-production-inhibitory assays
Peptide Sequence hOT7T022 HLWAR77
Binding
(IC50, nM)
cAMP
(EC50, nM)
Binding
(IC50, nM)
cAMP
(EC50, nM)
hRFRP-3-31 SAGATANLPLRSGRNMEVSLVRRVPNLPQRFamide 1.3 4.8 16 780
hRFRP-3-28 ATANLPLRSGRNMEVSLVRRVPNLPQRFamide 1.1 5.1 14 520
bRFRP-3-28 AMAHLPLRLGKNREDSLSRWVPNLPQRFamide 1.6 6.4 7.0 290
hRFRP-3-17 NMEVSLVRRVPNLPQRFamide 3.4 6.8 18 730
hRFRP-3-8 VPNLPQRFamide 1.2 4.1 150 >1000
hRFRP-3-7 PNLPQRFamide 0.62 3.0 110 >1000
hRFRP-3-6 NLPQRFamide 2.6 28 230 >1000
hRFRP-3-5 LPQRFamide 2.1 51 76 >1000
hRFRP-3-4/NPFF-4 PQRFamide 15 >1000 26 >1000
hRFRP-1-37 SLNFEELKDWGPKNVIKMSTPAVNKMPHSFANLPLRFamide 15 12 17 470
bRFRP-1-35 SLTFEEVKDWAPKIKMNKPVVNKMPPSAANLPLRFamide 21 14 47 >1000
hRFRP-1-20 MSTPAVNKMPHSFANLPLRFamide 5.0 2.8 3.1 410
hRFRP-1-12 MPHSFANLPLRFamide 2.7 4.8 3.8 330
hRFRP-1-5 LPLRFamide 2.5 23 16 790
hNPSF SQAFLFQPQRFamide 4.2 47 0.34 0.9
bNPSF SPAFLFQPQRFamide 4.0 81 0.36 1.2
bNPSF-10 PAFLFQLQRFamide 4.1 110 0.38 1.4
bNPSF-9 AFLFQPQRFamide 4.5 110 0.58 2.0
NPFF FLFQPQRFamide 2.4 120 1.0 6.9
NPFF-7 LFQPQRFamide 4.6 140 3.0 8.5
NPFF-6 FQPQRFamide 13 360 28 130
NPFF-5 QPQRFamide 21 430 69 >1000
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its binding affinity and cAMP-production-inhibitory activity
on the receptors, further supporting the view that N-terminal
Leu is crucial for cAMP-production-inhibitory activity on
hOT7T022. In the binding assays for HLWAR77, hRFRP-3-
4 and hRFRP-3-5 appeared to be more potent than hRFRP-3-
6, hRFRP-3-7, and hRFRP-8, suggesting that Asn at the N
terminus of RFRP-3 might slightly hinder the binding of
RFRP-3 to HLWAR77, although this residue did not appear
to hinder binding to hOT7T022.
In the competitive binding assays, NPFF efficiently
bound with both hOT7T022 (IC50 = 2.4 nM) and HLWAR77
(IC50 = 1.0 nM). In addition, it showed potent cAMP-pro-
duction-inhibitory activity on HLWAR77 (EC50 = 6.9 nM),
but weak activity on hOT7T022 (EC50 = 120 nM), suggest-
ing that NPFF is principally directed to HLWAR77 rather
than OT7T022 although it binds with both receptors. Iden-
tifying a novel form of bovine NPFF having three additional
amino acids at the N terminus (i.e., bNPSF), which corre-
sponded to hNPSF [10], we compared these peptides to
NPFF in their interaction with the receptors. In binding and
cAMP-production-inhibitory assays for hOT7T022, they
showed potency almost equivalent to NPFF. However, in
binding to HLWAR77, they were more potent than the
authentic form, suggesting that the three additional amino
acid residues enhanced interaction with HLWAR77.
NPFF-7 was almost equivalent to NPFF in its interaction
with the two receptors when examined in the binding and
cAMP-production-inhibitory assays, suggesting that the
seven-residue C-terminal (i.e., LFQPQRFamide) was
enough for complete interaction with the receptors. How-
ever, NPFF-6 showed lower binding affinity and cAMP-
production-inhibitory activity for the two receptors than
NPFF-7, suggesting that the N-terminal Leu of NPFF-7
played an important role for full interaction. NPFF-5 almost
completely lost cAMP-production-inhibitory activity for
HLWAR77, although it still retained binding activity for
OT7T022 and HLWAR77 and a very weak cAMP-produc-
tion-inhibitory activity for hOT7T022, suggesting that Phe at
the N terminus of NPFF-6 partly contributed to cAMP-
production-inhibitory activity on HLWAR77. As NPFF-5
was almost equivalent to NPFF-4 in its binding and cAMP-
production-inhibitory activity for the two receptors, Glu at
the N terminus of NPFF-5 did not appear to bear much
influence on the interaction.
4. Discussion
To demonstrate the existence of RFRP-3, we purified it
from bovine hypothalamus. The purified endogenous bovine
RFRP-3 was found to consist of 28 amino acid residues,
suggesting that its N terminus is produced by cleavage
between Arg103 and Ala104 in the RFRP preproprotein.
This was unexpected for the following reasons. (1) As basic
amino acid residues are known to be potential sites for
cleavage by proteases, the cleavage between Arg103 and
Ala104 in bovine preproRFRP appears to be rational. How-
ever, in the endogenous bovine RFRP-3 sequence, there are
four other basic amino acid residues, that is, Arg111, 116,
and 122 and Lys114. This unexpected processing of endog-
enous bovine RFRP-3 is similar to that seen in endogenous
RFRP-1 which also has a long N-terminal portion [2]. Thus,
not only the primary sequences, but also other factors such as
three-dimensional conformation might determine the selec-
tive cleavage of the N-terminal portions. (2) The N-terminal
portion of the endogenous RFRP-3 sequence included the
motif to generate the putative RFRP-2 sequence, that is,
AMALLPLRLGR. We have previously demonstrated that
synthetic human RFRP-2 did not bind to OT7T022 receptor
[1]. In consideration of this, RFRP-2 should not be produced
from bovine and human RFRP preproproteins. Nevertheless,
they appeared to be able to generate RFRP-2 in the primary
sequence. Another group has recently reported the identi-
fication of gonadotropin inhibitory hormone (GnIH) in quail
[11], which is thought to be the orthologue of RFRP.
Interestingly, GnIH preproprotein is also reportedly able to
produce three different peptides, corresponding to RFRP-1,
-2, and -3. Two of these peptides have been verified to exist
in the quail brain, that is, GnIH and GnIH-related peptide II
[12]. These are encoded in the preproprotein at positions
corresponding to RFRP-2 and RFRP-3, respectively. How-
ever, we have previously demonstrated that rat and mouse
RFRP preproproteins completely lack the sequence corre-
sponding to RFRP-2, suggesting that RFRP-2 retrogressed in
the evolution of mammals. As for endogenous RFRP-3, rat
hypothalamic RFRP-3 was recently determined to be an 18-
amino acid peptide [13], differing in length from that of
bovine endogenous RFRP-3. However, both peptides appear
to be correspondingly produced by cleavage at the C-
terminal side of Arg in the preproRFRPs, suggesting that
the same processing mechanism produces different lengths
of peptides between rat and cow.
We analyzed the tissue distribution of RFRP-3 in rats by
sandwich EIA, and found that RFRP-3 agreed well with
RFRP-1 in tissue distribution [2]. Both RFRP-1 and -3 were
localized principally in the central nervous system. The
highest concentrations of both peptides were detected in
the hypothalamus at comparable levels. These results sug-
gest that the two peptides are produced almost equally from
the RFRP preproprotein in tissues.
RFRP-3 and NPFF are closely related because they
possess the identical C-terminal sequence, PQRFamide.
HLWAR77 has recently been reported to be a specific
receptor for NPFF and NPAF [3]. NPGPR is nearly identical
to HLWAR77, and thought to be its counterpart in rat [14].
In addition, another group has reported two receptors, that
is, NPFF1 and NPFF2, for NPFF [5]. OT7T022 and
HLWAR77/NPGPR are identical to NPFF1 and NPFF2,
respectively. In this study, we prepared CHO cells express-
ing hOT7T022 or HLWAR77 and analyzed the interactions
of RFRP-3 and NPFF with these receptors. We assessed
their interactions by competitive binding and cAMP-pro-
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duction-inhibitory assays. In our experiments with RFRP-3
and NPFF C-terminal peptides, we found that PQRFamide,
which was common between the C-terminal portions of
RFRP-3 and NPFF, showed evident binding activity to both
receptors, but almost lost its cAMP-production-inhibitory
activity. This suggests that PQRFamide is a core structure
essential for binding to the receptors, but is not sufficient to
exhibit cAMP-production-inhibitory activity. We showed
that the seven-amino acid length C-terminal peptide of
RFRP-3 (hRFRP-3-7: PNLPQRFamide) and that of NPFF
with the same length (NPFF-7: LFQPQRFamide) showed
full interactions with hOT7T022 and HLWAR77, respec-
tively. These results suggest that the three amino acid residues
(i.e., PNL in RFRP-3 and LFQ in NPFF) added to the N
terminus of PQRFamide played important roles not only in
determining receptor specificities, but also in exhibiting full
cAMP-production-inhibitory activities. Among these three
amino acid residues, Pro and Leu were found to be partic-
ularly critical in the interaction of RFRP-3 with hOT7T022,
and Leu and Phe in that of NPFF with HLWAR77.
Our results indicate that at least in vitro, shorter RFRP-3
peptides — minimally, PNLPQRFamide — exhibit interac-
tion with the receptors as fully as the long endogenous
RFRP-3. Important residues in the sequence, that is, Pro,
Leu and PQRFamide, are conserved between human, bo-
vine, rat and mouse [1,2], whereas the N-terminal portion
shows diversity in both length and sequence. Endogenous
bovine RFRP-3, composed of 28 amino acids, is 10 amino
acids longer than endogenous rat RFRP-3 [13]. Although the
reason why natural RFRP-3 has such long, varying N-
terminal portions remains to be elucidated by future studies,
they may possess various functions in vivo.
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